Efficacy of Momordica charantia L. on Blood Glucose, Blood Lipid, and Body Weight: A Meta‑analysis of Randomized Controlled Trials

ABSTRACT

Background: Previous studies reported that Momordica charantia (MC) improves several metabolic parameters, yet outcomes from numerous trials are contradictory. Objectives: This study aimed to assess MC efficacy for improving glycemic status, lipid profile, and body weight. Materials and Methods: The databases included PubMed, Cochrane Register of Controlled Trials, Scopus, CINALH, AMED, ThaiLIS, and Thai Medical Index, from inception to June 2016. References from retrieved articles were also evaluated. For this analysis, we selected randomized placebo versus controlled intervention trials conducted in humans dosed with various forms of MC, excluding studies where patients coadministered other medications. We performed a quality assessment of the retrieved studies using Jadad’s scoring and Cochrane’s risk of bias assessment. Results: Eight studies (507 participants) met inclusion criteria, which included six randomized controlled trials (RCTs). Meta‑analysis revealed a reduction in fasting blood sugar (FBS) (weight mean difference [WMD] −25.03 mg/dL; 95% confidence interval [CI] −41.17,‑8.89) and hemoglobin A1C (HbA1C), favoring MC (WMD −0.20%; 95% CI −0.36, −0.04). Similar results were observed for LDL‑C (WMD −5.86 mg/dL; 95% CI: −10.83, −0.89), total cholesterol (WMD −6.29 mg/dL; 95% CI: −10.64, −1.93), and triglyceride (WMD −16.22 mg/dL; 95% CI: −26.40, −6.04). Moreover, patients administering MC experienced a significant reduction in body weight (WMD v3.45 kg; 95% CI −6.73, −0.16). Conclusions: MC may improve fasting blood glucose levels, lipid profile, or body weight. A large, well‑designed RCT and head‑to‑head comparison using a standardized preparation of MC will provide definitive data on specific participants.

KEYWORDS

• Blood glucose
• body weight
• lipid profile
• meta‑analysis
• Momordica charantia

Showing references and in-text citations exactly as published.

• DOI10.4103/pm.pm_215_17Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 14, ISSUE 56Yukgunja‑tang, a Traditional Herbal Formula, Attenuates Cigarette Smoke‑induced Lung Inflammation in a Mouse ModelEunsook Park, Woo‑Young Jeon, Chang‑Seob Seo, Hyekyung Ha, Seong Eun Jin, Jinhee Kim, Mee‑Young Lee · pp. 275–282Original ArticleSame type: Article
• Article · VOLUME 14, ISSUE 56Alleviation of Doxorubicin‑induced Hepatic Toxicity with Fermented Cordyceps sinensis via Regulating Hepatic Energy Metabolism in RatsPing‑An Yao, Rong Wu, Yao‑Li Zhang, Xiao‑Hua Cui, Ke‑Zhao Wei, Xu Xu, Jian‑Ping Gao · pp. 283–289Original ArticleSame type: Article
• Article · VOLUME 14, ISSUE 56Innovative Phytoformulation Containing Capsaicinoids: Microparticles Development, Analytical Method Validation, and Anti‑ulcer EffectMartinha A. Almeida, Jessica M. Nadal, Traudi Klein, Josiane P. de Paula, Jane M. Budel, Andressa Novatski, Eliane A. Campesatto, Paulo V. Farago · pp. 290–296Original ArticleSame type: Article
• Article · VOLUME 14, ISSUE 56Saponins from Rhizoma Panacis Majoris Attenuate Myocardial Ischemia/Reperfusion Injury via the Activation of the Sirt1/FoxO1/Pgc‑1α and Nrf2/Antioxidant Defense Pathways in RatsHai‑Bo He, Xiao‑Mei Li, Dao‑Jun Li, Yong‑Hong Ding, Yong‑Feng Zhang, Hai‑Yan Xu, Min‑Lu Feng, Chang‑Qing Xiang, Ji‑Gang Zhou, Ji‑Hong Zhang, Hong‑Jun Liu, Mao‑Hua Chen · pp. 297–307Original ArticleSame type: Article